Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer

Bilò, Maria Beatrice; Martini, Matteo; Berra, D.; Scarpa, Antonio; Losappio, Laura; Quercia, O; Rizzini, Fabio Lodi; Bignardi, Donatella; Cortellini, Gabriele; Zisa, Giuliana; Giúdice, Antonela Del; Manzotti, Giuseppina; Marcotulli, C.; Murzilli, F; Cilia, M.; Pravettoni, Valerio; Borrelli, Paolo; Pastorello, E. A.

doi:10.18176/jiaci.0242

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are no guidelines in the literature on the management of product deficiency during maintenance, which was reported in 2016 owing to the sudden unavailability of some extracts. A recent multicenter study prospectively collected data on switching VIT and reported that switching VIT from one manufacturer to another is a safe option, if necessary, in patients who had previously tolerated VIT, even without reducing the previous maintenance dose, in a proper medical setting staffed by experienced personnel [185,186]. In patients who experienced previous severe systemic reactions during VIT, the treatment should be restarted with a rush/ultrarush protocol in centers experienced in hymenoptera venom allergy and VIT or with a conventional protocol in less experienced centers.…”

Section: Protocolsmentioning

confidence: 99%

Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice

Bilò

Pravettoni

Bignardi

et al. 2019

J Investig Allergol Clin Immunol

Self Cite

115

View full text Add to dashboard Cite

Hymenoptera venom allergy is an epidemiologically underestimated condition representing an important cause of morbidity worldwide. Preventing future allergic reactions in patients who have developed a systemic reaction is based on the correct management of emergency followed by a correct diagnosis, prescription of adrenaline autoinjectors and, where indicated, specific venom immunotherapy (VIT). Some epidemiological studies highlight the poor knowledge of this disease and the frequent inadequacy of its management. Moreover, they emphasize the importance of such a life-saving treatment as specific immunotherapy. The availability of high quality Hymenoptera venom extracts for diagnostic and therapeutic use has dramatically improved the prognosis and the quality of life of allergic patients. The subcutaneous VIT represents the most effective form of immunotherapy with allergen presently available, with a carry-over effect lasting up to several years after its interruption. This report on the management of children and adults allergic to Hymenoptera venom was drawn up by a panel of Italian experts. The main objective of this consensus is to review the scientific evidences related to diagnosis, therapy and management of patients allergic to Hymenoptera venom and is aimed to improve the knowledge about this disease and promote good clinical practices. Practical suggestions for a correct diagnosis, prescription of emergency therapy and immunotherapy, as well as strategies for taking care of patients´ management are included.

show abstract

Section: Protocolsmentioning

confidence: 99%

Hymenoptera Venom Allergy: Management of Children and Adults in Clinical Practice

Bilò

Pravettoni

Bignardi

et al. 2019

J Investig Allergol Clin Immunol

Self Cite

115

View full text Add to dashboard Cite

show abstract

“…In case of shortage of venom extracts, the switch to another manufacturer can be performed safely, according to a recently proposed switch protocol using the same maintenance dose in subjects that previously tolerated a long-term VIT, while in case of documented SR during VIT, a safe option is to restart VIT from the build-up phase (90,91).…”

Section: Specific Venom Immunotherapy (Vit)mentioning

confidence: 99%

Clinical aspects of hymenoptera venom allergy and venom immunotherapy

Bilò

Tontini

Martini

et al. 2019

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

“…Overall, however, the available safety data on transitioning from aqueous to depot venom preparations are reassuring. 7,8 The depot Alutard SQ product cannot be used for intradermal testing, due to the inclusion of aluminium hydroxide. Sensitization should, therefore, be confirmed using skin prick testing using an available commercial kit and serum specific IgE testing.…”

Section: Switch-over From Pharmalgen To Alutard Bee and Wasp Venom Inmentioning

confidence: 99%

“…Such delayed reactions with alum‐based vaccines are uncommon and generally mild, although should be borne in mind when switching a patient from Pharmalgen to Alutard SQ. Overall, however, the available safety data on transitioning from aqueous to depot venom preparations are reassuring …”

mentioning

confidence: 99%